【摘要】 目的:观察重组人血小板生成素(recombinanthuman-thrombopoietin,rhTPO)治疗肿瘤化疗所致血小板减少的有效性及安全性。方法:回顾性分析我院经化疗后血小板计数≤50×109/L的肿瘤患者87例,分为rhTPO组45例和国产组白介素11(rhIL-11)组42例。rhTPO组给予rhTPO300u/kg,皮下注射每日1次,连续使用;rhIL-11组给予rhIL-111.5mg皮下注射,每日1次,连续使用;两组在用药过程中待血小板计数恢复至≥100×109/L以上或血小板计数绝对值升高≥50×109/L时即停用。结果:rhTPO组患者血小板计数恢复至100×109/L平均使用7天,有效率86.6%;rhIL-11组患者血小板计数恢复至100×109/L平均使用11天,有效率69%,两组疗效比较有统计学差异(P<0.05)。rhTPO组和rhIL-11组因出现出血症状而采取输注血小板患者例数分别为1例和3例。结论:rhTPO对肿瘤化疗所致的血小板减少症有效率高,起效快,安全性高,值得进一步推广。更多还原

【Abstract】 Objective:To investigate the effectiveness and safety of chemotherapy reduced thrombocytopenia with recombinant human thrombopoietin (RhTPO).Methods:Total of 87 cases were retrospectively analysed with platelet count lower than 50×109/L and divided into two groups,RhTPO group (45 cases) and domestic interleukin (rhIL-11) group (42 cases).In RhTPO group rhTPO was given 300u/kg,hypodermic once daily,in RhIL-11 group rhIL-11 to 1.5 mg subcutaneous injection,once per day,for two groups in the process of platelet counts to PTL above 100×109/L or platelet counts increase 50×109/L.Results:rhTPO group platelet count recovered to 100×109/L in seven days,and effective rate was 86.6%;RhIL-11 group to 100×109/L in 11 days,effective rate was 69% (P<0.05).Conclusion:rhTPO for chemotherapy induced thrombocytopenia is effective and safe.更多还原